Tide Has Turned on P&G's Sales Course, Shares Pricey

Wide-moat Procter & Gamble chalked up another quarter of strong sales and profit gains.

Securities In This Article
Procter & Gamble Co
(PG)

Even in the face of more robust comparisons, wide-moat Procter & Gamble PG chalked up another quarter of strong sales and profit gains, evidencing the prudence of its current strategic course (anchored in driving productivity savings to fuel continued investments behind consumer-valued innovation after pruning its mix over the past several years). In the quarter, organic sales popped 7% on a 290-basis-point and 260-basis-point expansion in adjusted gross and operating margins, respectively, to 51.3% and 24.3%. Not only did the firm’s top-line bump come on top of a 4% uptick in the year-ago period, but growth was fairly balanced between price (up 1%), mix (a 2% benefit), and volumes (4% higher).

As a result of the solid start to the year, management raised its sales and earnings guidance modestly, which now sits at 3%-5% growth (from 3%-4%) and 5%-10% (from 4%-9%) growth, respectively. While our prior 3% and 7% marks continue to align with the revised outlook, we will likely edge up our $103 per share valuation by a low-single-digit percentage to account for the continued outsize performance and the time value of money. However, we don’t anticipate altering our longer-term forecast of 3%-4% annual sales growth and more than 24% operating margins by fiscal 2029, up from an average of 21.6% over the past three years. Shares traded up by around a 3% clip following the print, and as such, sit at a lofty 15%-20% premium to our assessment of P&G’s intrinsic value.

We’ve long been in the camp that P&G was poised to boast more robust sales performance, but we aren’t blind to the fact that it will soon lap tougher comparisons (that inflate throughout the rest of the year) and persistent competitive headwinds (which could include increased promotional activity particularly if the raw material inflation remains tempered, inciting competitors to reduce prices to eat into P&G’s market share) that could derail its trajectory.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

About the Author

Erin Lash, CFA

Sector Director
More from Author

Erin Lash, CFA, is a sector director, AM Consumer, for Morningstar*. In addition to leading the sector team, she covers packaged food and household and personal care companies. Beyond managing a team of nine analysts and associates covering an array of consumer firms, Lash also conducts fundamental analysis of 13 multi-billion-dollar market capitalization firms in the packaged food and household and personal care space.

Before joining Morningstar in 2006, Lash spent four years as an investment analyst covering retail, transportation, and technology firms for State Farm Insurance. In this capacity, Lash analyzed financial statements, business strategy, and fundamentals of owned companies and potential investments, presenting her recommendations based on this analysis to State Farm portfolio managers for ownership consideration.

Lash holds a bachelor’s degree in finance from Bradley University’s Foster College of Business. She also holds a master’s degree in business administration, with concentrations in accounting and finance, from the University of Chicago Booth School of Business. Lash has completed the Chartered Financial Analyst® designation. She ranked second in the food and tobacco industry in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center